Published in Cancer Weekly, October 12th, 2004
At a median follow-up of 760 days, patients receiving 800 mg per day experienced 5 months longer progression-free survival compared to patients receiving the 400 mg daily...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.